Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $829.16 | 27 | 84.7% |
| Consulting Fee | $150.00 | 1 | 15.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $619.90 | 7 | $0 (2024) |
| Celgene Corporation | $165.11 | 19 | $0 (2020) |
| COMSORT, Inc | $150.00 | 1 | $0 (2018) |
| Exelixis Inc. | $44.15 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $99.99 | 1 | Astellas Pharma US Inc ($99.99) |
| 2023 | $99.95 | 1 | Astellas Pharma US Inc ($99.95) |
| 2022 | $179.98 | 2 | Astellas Pharma US Inc ($179.98) |
| 2021 | $163.99 | 2 | Astellas Pharma US Inc ($163.99) |
| 2020 | $241.10 | 20 | Celgene Corporation ($165.11) |
| 2018 | $150.00 | 1 | COMSORT, Inc ($150.00) |
| 2017 | $44.15 | 1 | Exelixis Inc. ($44.15) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/16/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.99 | General |
| 01/17/2023 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.95 | General |
| 10/24/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.99 | General |
| 03/07/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.99 | General |
| 07/06/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $64.99 | General |
| 02/19/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
| 12/17/2020 | Celgene Corporation | SPRYCEL (Drug) | Education | Cash or cash equivalent | $8.69 | General |
| Category: Oncology | ||||||
About Dr. Goran Broketa, MD
Dr. Goran Broketa, MD is a Hematology & Oncology healthcare provider based in Manchester, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033153374.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Goran Broketa, MD has received a total of $979.16 in payments from pharmaceutical and medical device companies, with $99.99 received in 2024. These payments were reported across 28 transactions from 4 companies. The most common payment nature is "Education" ($829.16).
Practice Information
- Specialty Hematology & Oncology
- Location Manchester, NH
- Active Since 06/16/2006
- Last Updated 11/12/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1033153374
Products in Payments
- SPRYCEL (Drug) $165.11
- KEYTRUDA (Biological) $150.00
- Cabometyx (Drug) $44.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Manchester
David Reisman, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $2,616
Dr. Karen Hoffmeister, D.o, D.O
Hematology & Oncology — Payments: $2,400
Dr. Eric Bonnem, Md, MD
Hematology & Oncology — Payments: $1,151
Gabriele Southgate, Md, MD
Hematology & Oncology — Payments: $65.15
Laura Salama, Md, MD
Hematology & Oncology